Safety and Tolerability of Repeat Courses of IM Alefacept

Summary

Previous Biogen studies have provided experience with the tolerability, immunogenicity, and efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage, experience in larger studies, as well as the FDA-approved labeling, is confined to treatment courses of 12 weeks. The purpose of the present study is to offer an extended course of therapy with alefacept.

Timeline

Start

2004-02

Primary completion

2005-12

Completion

2005-12

Drugs

Indications